The Weekly Roundup: September 2-6

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Dermatology Conferences and Meetings Calendar 2024: September

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Prostaglandin Analogues, Phosphodiesterase Inhibitors Effective in Vitiligo as Monotherapy or Add-On Modalities

42 studies with 1027 cases evaluated drugs like bimatoprost and apremilast for vitiligo.

Defining Photosensitivity in Atopic Dermatitis

A recent study revealed a spectrum of photosensitivity in AD, with varying symptoms and sensitivities.

Researchers Report Case of Patient With Mogamulizumab-Induced Vitiligo

The 83-year-old patient was being treated for mycosis fungoides.

Phase 2 Trial Begins for EVO756 in Chronic Inducible Urticaria

The phase 2 trial for EVO756, targeting mast cell-related CIndU, is now underway at 15 US study sites.

Oral Silymarin Plus Hair Follicle Transplantation Efficacious in Refractory Vitiligo

The study showed significant improvement in repigmentation with silymarin, with patients of different sexes benefiting equally, though monthly differences were not significant.

Journal Digest: September 3

This week’s collection of the latest dermatologic studies includes the implementation of an action plan for patients with atopic dermatitis, early childhood eczema and the risk of allergic multicomorbidities, and more.

Study Outlines Prurigo Nodularis and Psychiatric Comorbidities

The review found that patients with PN are approximately 1.3 times more susceptible to depression and 1.9 times more likely to experience anxiety.

POLL: When Do You Escalate AD Treatment if Treatment Targets are Not Achieved?

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

IBI363 Monotherapy Granted Fast Track Designation in US for Advanced Melanoma

The PD-1/IL-2α bispecific antibody fusion protein is intended for patients with unresectable locally advanced or metastatic melanoma.

Study Outlines Gap in HS Treatment Guidelines Across Specialties

Although clinicians showed similar antibiotic prescribing rates, the study highlights a need for better adherence to HS treatment guidelines across all specialties.

Q&A: Jeffrey Stricker, DO, MBA, Discusses Study on Image-Guided SRT in Non-Melanoma Skin Cancers

The study, published in Dermato, showed that 92% of NMSC tumors showed measurable changes in depth of invasion from one image to the next.

Study Links Sun Protection to Better QoL in Rosacea

The study stated that enhancing patient education and psychological support can improve rosacea management and quality of life.

Drug Survival of Biosimilars, Originator TNF Inhibitors Similar

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry.

Arcutis Enrolls Last Participant in ARQ-255 Trial for AA

Arcutis' study of ARQ-255 aims to address the lack of FDA-approved topical treatments for alopecia areata, a condition affecting roughly 1 in 500 people.

LEO Pharma Presents Prevalence, Severity, and Treatment CHECK Data for Chronic Hand Eczema

The data was presented at the European Society of Contact Dermatitis in Dresden, Germany, this week.

Denileukin Diftitox-cxdl Gains NCCN Category 2A Recommendation for Cutaneous T-cell Lymphoma Treatment

Citius' recently-approved Lymphir has been added to the National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology.

Advanced Laser Eases Acne Scars, Melasma, and Wrinkles

New research shows the 675-nm laser enhances skin texture and rejuvenation, making it a valuable tool for various dermatological conditions.

Exploring Afamelanotide for Vitiligo: Insights into the CUV 105 Phase 3 Clinical Trial

The study is actively recruiting participants at multiple sites across the US.

Approximately 65% of Dermatologists in Japan Report Dissatisfaction With Treatment Options for Severe Prurigo Nodularis

Researchers conducted a web-based survey to gain insights into current clinical practice for PN in Japan.

Abrocitinib Shows Promise for Prurigo Nodularis

The JAK1 inhibitor provided significant relief for 2 patients with refractory PN.

Exploring the Perception of Digital Health Tools in Dermatology

The JAK1 inhibitor provided significant relief for 2 patients with refractory PN.